JP2022535920A5 - - Google Patents

Info

Publication number
JP2022535920A5
JP2022535920A5 JP2021572548A JP2021572548A JP2022535920A5 JP 2022535920 A5 JP2022535920 A5 JP 2022535920A5 JP 2021572548 A JP2021572548 A JP 2021572548A JP 2021572548 A JP2021572548 A JP 2021572548A JP 2022535920 A5 JP2022535920 A5 JP 2022535920A5
Authority
JP
Japan
Prior art keywords
composition according
pharmaceutical composition
suramin
less
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021572548A
Other languages
English (en)
Japanese (ja)
Other versions
JP7749169B2 (ja
JP2022535920A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031217 external-priority patent/WO2020247127A1/en
Publication of JP2022535920A publication Critical patent/JP2022535920A/ja
Publication of JP2022535920A5 publication Critical patent/JP2022535920A5/ja
Application granted granted Critical
Publication of JP7749169B2 publication Critical patent/JP7749169B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021572548A 2019-06-07 2020-05-02 中枢神経系障害を処置するための組成物および方法 Active JP7749169B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962858621P 2019-06-07 2019-06-07
US62/858,621 2019-06-07
PCT/US2020/031217 WO2020247127A1 (en) 2019-06-07 2020-05-02 Compositions and methods for treating central nervous system disorders

Publications (3)

Publication Number Publication Date
JP2022535920A JP2022535920A (ja) 2022-08-10
JP2022535920A5 true JP2022535920A5 (enExample) 2023-05-23
JP7749169B2 JP7749169B2 (ja) 2025-10-06

Family

ID=73652889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572548A Active JP7749169B2 (ja) 2019-06-07 2020-05-02 中枢神経系障害を処置するための組成物および方法

Country Status (8)

Country Link
US (1) US20220226268A1 (enExample)
EP (1) EP3979985A4 (enExample)
JP (1) JP7749169B2 (enExample)
CN (1) CN114340597B (enExample)
AU (1) AU2020288999A1 (enExample)
CA (1) CA3142842A1 (enExample)
IL (1) IL288655A (enExample)
WO (1) WO2020247127A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116867487A (zh) * 2020-07-29 2023-10-10 完美日光有限公司 苏拉明的制造方法
US20230390226A1 (en) * 2020-10-22 2023-12-07 Paxmedica, Inc. Intranasal administration of suramin for treating nervous system disorders
IL302224A (en) * 2020-10-22 2023-06-01 Paxmedica Inc Administration of anti-purinergic preparations for the treatment of disorders of the nervous system
WO2023027994A1 (en) * 2021-08-23 2023-03-02 Paxmedica, Inc. Methods for treating nervous system disorders with antipurinergic agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002266A1 (en) * 1984-10-12 1986-04-24 United States Of America, Represented By The Unite Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav)
AU6527300A (en) * 1999-08-11 2001-03-05 Josef Pitha Potentiation of inclusion complex formation of cyclodextrin derivatives
US20050063940A1 (en) * 2002-02-25 2005-03-24 Sveinbjorn Gizurarson Bioadhesive agent
FR2867682B1 (fr) * 2004-03-22 2009-06-05 Galderma Res & Dev Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
EP1802287A2 (en) * 2004-09-27 2007-07-04 Sigmoid Biotechnologies Limited Minicapsule formulations
AU2007229866A1 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
FR2912591B1 (fr) * 2007-02-12 2009-05-01 Oberthur Card Syst Sa Procede et dispositif pour controler l'execution d'au moins une fonction dans un module de communication sans fil de courte portee d'un appareil mobile.
AR062239A1 (es) * 2007-08-07 2008-10-22 Civil De Estudios Superiores A Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal
US20120070487A1 (en) * 2010-03-24 2012-03-22 Aegis Therapeutics Llc Alkylsaccharide compositions with nutraceuticals
GB201401904D0 (en) * 2014-02-04 2014-03-19 Ziarco Pharma Ltd Pharmaceutical composition for topical administration
FR3025110B1 (fr) 2014-09-02 2016-12-23 Univ Francois-Rabelais De Tours Dispositif de pulverisation nasale de produit fluide
EP4541420A3 (en) * 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
JP7093559B2 (ja) * 2016-04-12 2022-06-30 トライジェミナ， インコーポレイテッド マグネシウム含有オキシトシン製剤および使用の方法
WO2018013811A1 (en) * 2016-07-14 2018-01-18 The Regents Of The University Of California Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders
WO2018148262A1 (en) * 2017-02-08 2018-08-16 Csp Pharma, Inc. Antipurinergic compounds and uses thereof
CN118697876A (zh) * 2017-02-09 2024-09-27 完美日光有限公司 用于自闭症谱系障碍药物治疗的方法
US11110060B2 (en) * 2017-10-25 2021-09-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents

Similar Documents

Publication Publication Date Title
JP2022535920A5 (enExample)
AU2018204865B2 (en) Anticonvulsant activity of steroids
EP3372229B1 (en) Methods of increasing tonic inhibition and treating angelman syndrome
JP6112867B2 (ja) サキシトキシン誘導体での触覚の喪失の処置
CN102159244A (zh) 包含减充血剂和皮质类固醇的鼻内组合物
JP2020502206A (ja) Ｔａｓｋ−１およびｔａｓｋ−３チャネル阻害剤を含む医薬剤形、ならびに呼吸障害療法におけるその使用
NO334441B1 (no) Preparat for behandling av vanlig forkjølelse.
AU2017379245A1 (en) Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy
AU2008259864B2 (en) Methods and compositions for administration of Oxybutynin
KR102375232B1 (ko) 비강내 에피네프린 제제 및 질환의 치료 방법
MX2010014223A (es) Composiciones pediatricas para el tratamiento de esclerosis multiple.
JP2021095420A (ja) エピナスチン又はその塩を含有する水性医薬組成物
KR20240069750A (ko) 신경 장애의 치료
JP2023546923A5 (enExample)
JP2022062596A (ja) エピナスチン又はその塩を含有する花粉破裂抑制剤
CN114903840A (zh) 一种治疗抑郁症的低剂量r-氯胺酮经鼻药物
US10966988B2 (en) Method for smoking cessation
WO2025196662A1 (en) Compositions and methods for treating eating disorders
KR20230031214A (ko) 적응 장애의 치료
JP2025160345A (ja) 薬学的組成物
EP3338764A1 (de) Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen
WO2025022362A1 (en) Compositions and methods for treating dyskinesia
TW201717936A (zh) 噴霧器用組成物
WO2022232347A1 (en) Use of perillyl alcohol to enhance levo-dopa delivery
HK40091740A (zh) 用於治疗、改善或预防微生物感染的制造产品和方法